Sex-informed precision immuno-oncology in bladder cancer: CD276 expression, Y loss, FGFR3 mutations, and beyond

Current Urology · Published 2026-02-27 · DOI 10.1097/cu9.0000000000000342

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1097/cu9.0000000000000342

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• A rare case of a young girl with genital manifestations of Proteus syndrome · Current Urology · 2026 · Same journal
• Causal relationships between plasma metabolites and prostate cancer: A Mendelian randomization study exploring immune and inflammatory mediators · Current Urology · 2025 · Same journal
• Advancing anatomical illustrations for radical prostatectomy: Enhancing depictions of urethral and detrusor architecture to reflect contemporary surgical concepts · Current Urology · 2026 · Same journal
• Advances in robot-assisted upper urinary tract reconstruction: Surgical techniques, emerging technologies, and complex clinical scenarios · Current Urology · 2026 · Same journal
• A case series and literature review of renal anastomosing hemangioma: An often-misdiagnosed benign tumor · Current Urology · 2025 · Same journal
• Nonfunctional ectopic adrenocortical adenoma dorsal to the kidney · Current Urology · 2025 · Same journal
• A Chinese expert consensus on prostate-pelvic syndrome · Current Urology · 2026 · Same journal
• What drives men to BPH surgery? A multidomain analysis of patient-reported outcomes before BPH intervention · Current Urology · 2026 · Same journal
• Transforming urological care: Physician and patient insights on artificial intelligence integration · Current Urology · 2026 · Same journal
• Application of rapidly prepared nonactivated high-efficiency chimeric antigen receptor T cells in the treatment of bladder cancer · Current Urology · 2026 · Same journal